Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma.
immune checkpoint-inhibitor
long-term survival
metastatic melanoma
nation-wide
real-life
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
11 Sep 2020
11 Sep 2020
Historique:
received:
11
08
2020
revised:
06
09
2020
accepted:
08
09
2020
entrez:
16
9
2020
pubmed:
17
9
2020
medline:
17
9
2020
Statut:
epublish
Résumé
Approval of immune checkpoint-inhibitors (ICIs) and BRAF-inhibitors has revolutionized the treatment of metastatic melanoma. Although these drugs have improved overall survival (OS) in clinical trials, real-world evidence for improved long-term survival is still scarce. Clinical data were extracted from the Danish Metastatic Melanoma database. This nation-wide cohort contains data on all patients who received systemic treatment for metastatic melanoma between 2008 and 2016. Ipilimumab, the first approved ICI, was implemented as standard-of-care in Denmark in 2012. Hence, patients were divided in a pre-ICI (2008-2011) and an ICI (2012-2016) era. Patients were defined as long-term survivors if they were alive 3 years after initiation of systemic therapy. Data from 1754 patients were retrieved. Patients treated in the ICI era had an improved median OS (11.3 months, 95% confidence interval (CI) 10.3-12.3) compared with those in the pre-ICI era (median OS 8.3 months, 95% CI 7.4-9.5,
Identifiants
pubmed: 32932758
pii: cancers12092591
doi: 10.3390/cancers12092591
pmc: PMC7564087
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : The Danish Ministry of Finance
ID : 4-1612-236/8
Références
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Lancet. 2017 Oct 21;390(10105):1853-1862
pubmed: 28822576
N Engl J Med. 2011 Jun 30;364(26):2507-16
pubmed: 21639808
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
Lancet Oncol. 2017 May;18(5):611-622
pubmed: 28359784
Eur J Cancer. 2017 Mar;74:89-95
pubmed: 28335891
Eur J Cancer. 2019 Feb;108:25-32
pubmed: 30605822
Eur J Cancer. 2019 Jul;115:61-67
pubmed: 31108244
Melanoma Res. 2017 Aug;27(4):358-368
pubmed: 28509765
J Clin Oncol. 2007 Apr 20;25(12):1562-9
pubmed: 17443000
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Cancer Immunol Immunother. 2018 Dec;67(12):1833-1844
pubmed: 30191256
N Engl J Med. 2014 Nov 13;371(20):1877-88
pubmed: 25265492
JAMA Dermatol. 2015 Oct;151(10):1087-95
pubmed: 26061591
N Engl J Med. 2014 Nov 13;371(20):1867-76
pubmed: 25265494